BURLINGTON, N.C. - Labcorp (NYSE: LH), a provider of laboratory services, announced the release of a new blood test that detects phosphorylated tau 217 (pTau217), a biomarker for Alzheimer's disease.
BURLINGTON, N.C. - Labcorp (NYSE:LH), a prominent healthcare diagnostics provider with a market capitalization of $23.5 billion, announced Thursday it will offer the Elecsys pTau181 test nationwide by ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Labcorp is now offering a blood-based biomarker test in ...
Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April 15, ...
Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...
BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid ...
BURLINGTON, N.C., Oct. 23, 2025 /PRNewswire/ -- Labcorp, a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood ...
A screenshot of Labcorp’s website seen July 3. The health care entity is no longer operating lab sites that serve within the Virginia Mason Franciscan Health network in Pierce and South King counties, ...
Lumipulse® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback